Alphatec Announces Commercial Launch of ALIF IdentiTi™ Porous Titanium Interbody System Implant
July 18 2019 - 9:00AM
Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a
medical device company dedicated to revolutionizing the approach to
spine surgery, announced today the commercial release of its
IdentiTi Large Window Porous Titanium Interbody Implant System for
anterior lumbar interbody fusion (ALIF) procedures.
“The spine market’s new organic innovation
machine continues to deliver meaningful clinical distinction,” said
Pat Miles, Chairman and Chief Executive Officer. “With this
fifth of twelve new product releases expected for 2019, ATEC is on
track to fulfill its aggressive new product development and
commercialization program. The innovation we are introducing is
increasingly being adopted by discriminating spine surgeons.”
ALIF IdentiTi-LW Porous Titanium
Interbody Implant System
The launch of the IdentiTi Interbody Implant
System follows successful alpha evaluations that began in December
2018. It marks the fourth of six IdentiTi implant systems the
Company expects to commercially introduce in 2019.
The IdentiTi line of implant systems is
manufactured using a subtractive process, which begets more
predictable performance, consistent bone-like porosity, and
enhanced imaging characteristics. IdentiTi implants not only
complement the Company’s current suite of PEEK implants, but also
allow ATEC to address the broader market of surgeons who prefer
titanium.
“IdentiTi ALIF is one of the first porous
titanium ALIF implant solutions to provide a truly unique
combination of implant material and geometry,” said Dr. Vedat
Deviren, Professor of Orthopaedic Surgery at UCSF Spine
Center. “With a porosity and stiffness similar to bone,
combined with a wide range of lordotic implant options, including
20-degree and 30-degree, IdentiTi ALIF is my preferred anterior
column interbody device.”
Key Features of the IdentiTi Porous
Titanium Interbody Systems
ATEC’s IdentiTi Porous TI Interbody Systems
offer implant options that are designed to provide the biological,
biomechanical, and imaging characteristics that surgeons seek in a
fusion construct. IdentiTi implants take advantage of bone’s
affinity for titanium, and because of their porosity, have a
surface roughness that enhances stability.
Key features include:
- Consistent, fully interconnected porosity throughout the
implant designed to mimic the structure and porosity of cancellous
bone;
- Proprietary pore structure designed to create surface roughness
that enhances immediate implant stability and facilitates surface
adhesion;
- Reduced density (60% porous), which enhances intraoperative and
postoperative imaging;
- Stiffness similar to bone;
- Subtractive manufacturing process, which creates a consistent
porous titanium material that furthers product performance
predictability with consistent and reproducible interconnected pore
sizes; and
- Intuitive, low profile, and exacting instruments designed to
optimize the surgeon experience and facilitate outstanding patient
outcomes.
About Alphatec Holdings,
Inc.
Alphatec Holdings, Inc., through its
wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp
Surgical, Inc., is a medical device company dedicated to
revolutionizing the approach to spine surgery. ATEC designs,
develops and markets spinal fusion technology products and
solutions for the treatment of spinal disorders associated with
disease and degeneration, congenital deformities and trauma. The
Company markets its products in the U.S. via independent sales
agents and a direct sales force.
Additional information can be found at
www.atecspine.com.
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve risks and uncertainty. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. The Company cautions investors that
there can be no assurance that actual results will not differ
materially from those projected or suggested in such
forward-looking statements as a result of various factors.
Forward-looking statements include references to the Company’s
planned commercial launches, product introductions and product
integration, surgeon and market acceptance of Company products,
solutions and platforms, and the Company’s ability to deliver key
product features. The important factors that could cause
actual operating results to differ significantly from those
expressed or implied by such forward-looking statements include,
but are not limited to: the uncertainty of success in developing
new products or products currently in the Company’s pipeline;
failure to achieve acceptance of the Company’s products by the
surgeon community; failure to obtain FDA or other
regulatory clearance or approval for new products, or unexpected or
prolonged delays in the process; continuation of favorable third
party reimbursement for procedures performed using the Company’s
products; the Company’s ability to compete with other products and
with emerging new technologies; product liability exposure; patent
infringement claims; and claims related to the Company’s
intellectual property. The words “believe,” “will,” “should,”
“expect,” “intend,” “estimate,” “look forward” and “anticipate,”
variations of such words and similar expressions identify
forward-looking statements, but their absence does not mean that a
statement is not a forward-looking statement. A further list
and description of these and other factors, risks and uncertainties
can be found in the Company's most recent annual report, and any
subsequent quarterly and current reports, filed with
the Securities and Exchange Commission. ATEC disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, unless required by law.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/883d7bf6-13a2-4936-a967-9f067b020841
Investor/Media Contact:
Tina Jacobsen
Investor Relations
(760) 494-6790
ir@atecspine.com
Company Contact:
Jeff Black
Chief Financial Officer
Alphatec Holdings, Inc.
ir@atecspine.com
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Apr 2023 to Apr 2024